Dhansa Labs

Why is Ambey Laboratories Ltd falling/rising?

As of 18-Jul, the stock price of Dhansa Labs Ltd is declining, currently at 21.85, reflecting a significant year-to-date drop of 50.40%. The stock is underperforming its sector and trading below all moving averages, indicating a bearish trend and decreased investor interest.

As of 18-Jul, the stock price of Dhansa Labs Ltd is falling, currently at 21.85, which reflects a decrease of 1.15 or 5.0%. This decline is evident in the stock's performance over various periods, showing a weekly drop of 5.00%, a monthly decrease of 2.89%, and a significant year-to-date decline of 50.40%. In comparison, the benchmark Sensex has shown positive returns during these periods, with a 1-week increase of 0.53% and a year-to-date decline of only 6.87%. <BR><BR>Additionally, today's performance indicates that Dhansa Labs has underperformed its sector by 4%. The stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Furthermore, there has been a notable drop in investor participation, with delivery volume on 16 July falling by 66.67% compared to the 5-day average. This lack of interest from investors contributes to the stock's declining price. Overall, these factors collectively explain the downward movement of Dhansa Labs Ltd's stock price.

Which are the latest news on Dhansa Labs?

What does Dhansa Labs do?

Dhansa Labs Ltd operates in the Pesticides & Agrochemicals industry as a Micro Cap company, reporting net sales of 41 Cr and a net profit of 2 Cr for the quarter ending March 2026. The company has a market cap of INR 57 Cr and key metrics include a P/E ratio of 9.00 and a return on equity of 7.26%.

Overview:<BR>Dhansa Labs Ltd operates in the Pesticides & Agrochemicals industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated as "Ambey Laboratories Private Limited" in 1985. It later converted to a Public Limited Company and changed its name to "Ambey Laboratories Limited" in December 2014. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 41 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 57 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 9.00 <BR>Industry P/E: 29 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.49 <BR>Return on Equity: 7.26% <BR>Price to Book: 0.72 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Dhansa Labs?

As of 10th June, Dhansa Labs Ltd has a market capitalization of 57.00 Cr, with recent net sales of 73.36 Cr and a net profit of 2.90 Cr. The balance sheet for March 2025 shows shareholder's funds of 76.35 Cr and total assets of 125.79 Cr.

As of 10th June, Dhansa Labs Ltd has a market capitalization of 57.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest two quarters, the company reported Net Sales of 73.36 Cr and a Net Profit of 2.90 Cr. This performance reflects the financial results for the periods ending March 2026 and December 2025.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 76.35 Cr and Total Assets of 125.79 Cr.

Who are the peers of the Dhansa Labs?

Dhansa Labs' peers include Shivalik Rasayan, Crop Life Science, Aristo Bio-Tech, Aimco Pesticides, Bhaskar Agrochem, Super Crop Safe, Adarsh Plant, and Phyto Chem (I). In terms of performance, Aimco Pesticides leads with a 1-year return of 0.00%, while Dhansa Labs has a return of -45.06%.

Peers: The peers of Dhansa Labs are Shivalik Rasayan, Crop Life Scienc, Aristo Bio-Tech, Aimco Pesticides, Bhaskar Agrochem, Super Crop Safe, Adarsh Plant, and Phyto Chem (I).<BR><BR>Quality Snapshot: Excellent management risk is observed at Shivalik Rasayan, while Average management risk is found at Crop Life Scienc and Aristo Bio-Tech, and the rest have Below Average management risk. Growth is Average at Aristo Bio-Tech, Below Average at Shivalik Rasayan, Crop Life Scienc, Dhansa Labs, Aimco Pesticides, Super Crop Safe, Adarsh Plant, and Phyto Chem (I), and the rest have Below Average growth. Capital Structure is Excellent at Shivalik Rasayan, Below Average at Crop Life Scienc, Dhansa Labs, Aimco Pesticides, Super Crop Safe, Adarsh Plant, Phyto Chem (I), and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aimco Pesticides at 0.00%, while the peer with the lowest is Shivalik Rasayan at -57.23%. Dhansa Labs has a 1-year return of -45.06%, which is better than Shivalik Rasayan but worse than Aimco Pesticides. Additionally, all peers except Aimco Pesticides, Bhaskar Agrochem, Super Crop Safe, Adarsh Plant, and Phyto Chem (I) have negative six-month returns.

How has been the historical performance of Ambey Laborator.?

Ambey Laborator has shown steady growth in net sales, increasing from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, but faced a decline in profit after tax to 4.78 Cr in Mar'25. The company has negative cash flow from operating activities, indicating liquidity challenges, despite a significant inflow from financing activities.

Answer:<BR>The historical performance of Ambey Laborator shows a steady growth in net sales and total operating income over the past four years, with figures rising from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25. The total expenditure has also increased, reflecting higher raw material costs, which rose from 69.91 Cr in Mar'22 to 118.83 Cr in Mar'25. Operating profit, excluding other income, has fluctuated slightly, peaking at 11.50 Cr in Mar'25, while profit before tax increased to 6.04 Cr in the same period. However, profit after tax saw a decline to 4.78 Cr in Mar'25 from 7.72 Cr in Mar'24. The company's equity capital has grown significantly, reaching 24.95 Cr in Mar'25, and total liabilities increased to 125.79 Cr, driven by a rise in short-term borrowings. Cash flow from operating activities has been negative, indicating challenges in cash generation, while cash flow from financing activities has provided a net inflow of 48.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Ambey Laborator's financial performance has demonstrated a consistent upward trend in net sales, which increased from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, alongside total operating income that mirrored this growth. The company's total expenditure also rose, primarily due to escalating raw material costs, which climbed from 69.91 Cr to 118.83 Cr over the same period. Operating profit, despite some fluctuations, reached 11.50 Cr in Mar'25, contributing to a profit before tax of 6.04 Cr. However, profit after tax decreased to 4.78 Cr in Mar'25, down from the previous year's 7.72 Cr. The equity capital has notably increased to 24.95 Cr, while total liabilities surged to 125.79 Cr, largely due to a significant rise in short-term borrowings. The cash flow from operating activities has been negative, indicating potential liquidity issues, although cash flow from financing activities has provided a substantial inflow, reflecting the company's reliance on external financing to support its operations.

Is Ambey Laborator. overvalued or undervalued?

As of September 23, 2025, Ambey Laborator is considered very expensive and overvalued with a PE Ratio of 21.92 and an EV to EBITDA of 15.02, significantly underperforming with a -39.55% return compared to the Sensex's -2.97%.

As of 23 September 2025, the valuation grade for Ambey Laborator. has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 21.92, an EV to EBITDA of 15.02, and a ROE of 6.26%. <BR><BR>In comparison to its peers, UPL has a PE Ratio of 38.05 and an EV to EBITDA of 9.17, while P I Industries is also very expensive with a PE of 34.2 and an EV to EBITDA of 24.36. Ambey Laborator.'s valuation appears stretched relative to these peers, highlighting its overvaluation status. Notably, over the past year, the stock has underperformed with a return of -39.55%, contrasting sharply with the Sensex's decline of only -2.97%.

Who are the top shareholders of the Ambey Laborator.?

The top shareholder of Ambey Laborator is Sarina Gupta, holding 68.49% of the shares, with no pledged promoter holdings. Public shareholders include Nakshatra Stressed Assets Fund Scheme I at 1.65% and individual investors collectively holding 22.4%.

The top shareholders of Ambey Laborator are primarily the promoters, with Sarina Gupta holding the highest stake at 68.49%. There are no pledged promoter holdings. In terms of public shareholders, the highest is Nakshatra Stressed Assets Fund Scheme I, which holds 1.65%. Additionally, individual investors collectively hold 22.4% of the shares. There is also one foreign institutional investor (FII) with a very small holding of 0.01%.

What is the technical trend for Ambey?

As of May 19, 2025, Ambey's technical trend is mildly bearish, influenced by daily moving averages and OBV, despite a mildly bullish weekly MACD.

As of 19 May 2025, the technical trend for Ambey has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages and Bollinger Bands are both showing mildly bearish signals. The weekly KST is bearish, and the OBV is also mildly bearish. The Dow Theory shows no trend in both weekly and monthly time frames. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the OBV.

When is the next results date for Ambey?

No Upcoming Board Meetings

Has Ambey declared dividend?

No Dividend History Available